Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer

Inclusion Criteria: * Subjects with pathologically or cytologically documented stage IIIB or IV NSCLC. Disease must be newly diagnosed . * Presence of at least 1 uni-dimensionally measurable index lesion,with the longest diameter ≥ 20 mm using conventional computer tomography(CT)/magnetic resonance imaging(MRI)scan or ≥ 10 mm using spiral computed tomography scan. * Age \> 18 and \< 65, with ECOG performance status 0-1,and Life expectancy of more than 3 months. * functions of major organs (haemogram, heart, liver, kidney) are basically normal, White blood count ≥3.5 x 109/L with neutrophils ≥1.5 x 109/L, platelet count≥100 x 109/L, and hemoglobin ≥100g/L. Total bilirubin ≤1.5 times upper limit of normal (ULN) range; alkaline phosphatase(ALP)≤ 2.5 times ULN or ≤5 times ULN (liver metastasis); Transaminases AST (SGOT) and ALT (SGPT) ≤ 2.5 times ULN or ≤ 5 times ULN (liver metastasis). serum creatinine ≤ 1.2 times ULN, blood urea nitrogen≤ 1.2 times ULN. * both female and male patients must use adequate methods of contraception. * without other malignancy history, except curative carcinoma in situ of cervix and skin basal cell carcinoma. * willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion Criteria: * Previous radiotherapy（except the radiotherapy of brain metastasis）, Previous chemotherapy or anticancer biotherapy , Participation other clinical trials within 1 month prior to inclusion in the trial. * With only unmeasureable lesion, ie, hydrothorax, ascites, lymphangitis carcinomatous, diffuse liver metastasis, bony metastasis; no measureable lesion or the lesion could not be determined. * Pregnant or breast-feeding women or using a prohibited contraceptive method. * With Symptomatic brain metastasis not controlled. * with an uncontrolled seizure disorder, or active centre neurological disease, or Psychiatric disease affected cognitive ability; physiogenic or pathological dystrophinopathies, chronic diarrhea, cachexia. * with significant history of cardiac disease, i.e., congestive heart failure, angina requiring medication, uncontrolled cardiac ventricular arrythmias, heart valve disease, serious myocardial infarction, uncontrolled hypertension. * With other serious internal diseases or uncontrolled infection. * With drug addition,ie,drug-taking,drug-taking for long time;with AIDS. * With organ transplantation,or using adrenocortical hormone or immunosuppressive agents for long time. * With history of serious allergic or allergy. * Not fit for the clinical trial judged by the investigator.